BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tango Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Tango Therapeutics's drugs run\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06810544-2771@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:TNG456: Phase 1/2 readout est. (NCT06810544)
DESCRIPTION:TNG456\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Safety
  and Tolerability of TNG456 Alone and in Combination With Abemaciclib in P
 atients With Solid Tumors With MTAP Loss\nEstimated primary completion: 31
  March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tng456#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06810
 544
URL:https://assetmemo.bio/drug/tng456#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05732831-2073@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Vopimetostat: Phase 1/2 readout est. (NCT05732831)
DESCRIPTION:Vopimetostat\, phase 1/2.\nStudy: Safety and Tolerability of TN
 G462 in Patients With MTAP-deleted Solid Tumors\nEstimated primary complet
 ion: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vopim
 etostat#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05732831
URL:https://assetmemo.bio/drug/vopimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06922591-2073@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Vopimetostat: Phase 1/2 readout est. (NCT06922591)
DESCRIPTION:Vopimetostat\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Study to Evaluate the Safety\, Tolerability & Efficacy of TNG462 in Combin
 ation in PDAC & NSCLC Patients\nEstimated primary completion: June 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/vopimetostat#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06922591
URL:https://assetmemo.bio/drug/vopimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07897734-2073@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20311130
DTEND;VALUE=DATE:20311201
SUMMARY:Vopimetostat: Phase 1/2 readout est. (NCT07897734)
DESCRIPTION:Vopimetostat\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 TNG462-C103: Study to Evaluate the Safety\, Tolerability\, and Antitumor A
 ctivity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Pa
 tients\nEstimated primary completion: November 2031. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/vopimetostat#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07897734
URL:https://assetmemo.bio/drug/vopimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
